MARKET

ALLO

ALLO

Allogene Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

34.79
-3.21
-8.45%
After Hours: 34.79 0 0.00% 16:00 09/21 EDT
OPEN
37.32
PREV CLOSE
38.00
HIGH
37.78
LOW
34.34
VOLUME
663.67K
TURNOVER
--
52 WEEK HIGH
55.00
52 WEEK LOW
17.43
MARKET CAP
4.85B
P/E (TTM)
-16.5108
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Allogene Therapeutics (ALLO) Down 9.9% Since Last Earnings Report: Can It Rebound?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/04 15:31
Allogene Therapeutics Announces September 2020 Virtual Investor Conference Participation
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in the following virtual
GlobeNewswire · 09/02 13:30
Allogene's (ALLO) Q2 Loss Widens Y/Y, Pipeline Progresses
Allogene (ALLO) reports no revenues for the second quarter of 2020.
Zacks · 08/06 15:19
Allogene Therapeutics EPS beats by $0.01
Allogene Therapeutics (NASDAQ:ALLO): Q2 GAAP EPS of -$0.53 beats by $0.01. Cash, equivalents and investments of $1.11B Press Release
seekingalpha · 08/05 16:34
Allogene Therapeutics Q2 EPS $(0.53) Beats $(0.54) Estimate
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.54) by 1.85 percent. This is a 29.27 percent decrease over losses of $(0.41) per share
Benzinga · 08/05 11:43
Allogene Therapeutics Q2 EPS $(0.53) Beats $(0.54) Estimate
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.54) by 1.85 percent. This is a 29.27 percent decrease over losses of $(0.41) per share
Benzinga · 08/05 11:43
Allogene Therapeutics Reports Second Quarter 2020 Financial Results
* Initial Phase 1 Results from the ALLO-501 ALPHA Trial at ASCO Demonstrated an Overall Response Rate of 75% and Complete Response Rate of 44% in CAR T Naïve Relapsed/Refractory Non-Hodgkin Lymphoma Patients * In the ALPHA Trial, Higher Dose ALLO-647 was As
GlobeNewswire · 08/05 11:30
Allogene Therapeutics to Report Second Quarter 2020 Financial Results on August 5, 2020
* Conference Call and Webcast Scheduled for 5:30 AM PT/8:30 AM ET SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T
GlobeNewswire · 07/28 12:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALLO stock price target is 53.67 with a high estimate of 70.00 and a low estimate of 37.00.
EPS
Institutional Holdings
Institutions: 207
Institutional Holdings: 91.20M
% Owned: 65.47%
Shares Outstanding: 139.29M
TypeInstitutionsShares
Increased
54
15.40M
New
77
3.89M
Decreased
37
4.64M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.94%
Pharmaceuticals & Medical Research
-2.24%
Key Executives
Chairman/Executive Director
Arie Belldegrun
President/Chief Executive Officer/Co-Founder/Director
David Chang
Co-Founder/Director
Joshua Kazam
Chief Financial Officer/Primary Contact
Eric Schmidt
Executive Vice President
Rafael Amado
Chief Technology Officer
Alison Moore
Chief Compliance Officer/General Counsel
Veer Bhavnagri
Lead Director/Independent Director
David Bonderman
Independent Director
John DeYoung
Independent Director
Franz Humer
Independent Director
Deborah Messemer
Independent Director
Todd Sisitsky
Independent Director
Owen Witte
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average ALLO stock price target is 53.67 with a high estimate of 70.00 and a low estimate of 37.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ALLO
Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company. The Company is focused on developing and commercializing of allogeneic T cell therapies for the treatment of cancer. It is involved in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and T cell manufacturing technologies. Its T cell product candidates are designed to target and kill cancer cells. Its product candidate includes UCART19, ALLO-501, ALLO-715 and ALLO-647. The Company’s UCART19 is an allogeneic CAR T cell therapy that targets CD19. The Company’s ALLO-501 is an allogeneic anti-CD19 CAR T cell product candidate, which is designed for the treatment of patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL). The Company’s ALLO-715 targets B-cell maturation antigen (BCMA) for the treatment of patients with R/R multiple myeloma.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Allogene Therapeutics Inc stock information, including NASDAQ:ALLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALLO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALLO stock methods without spending real money on the virtual paper trading platform.